• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2021, Vol. 38 ›› Issue (1): 70-73.

• 药物经济学评价 • 上一篇    下一篇

2种方案治疗儿童咳嗽变异性哮喘的疗效及药物经济学评价

陶兴茹, 刘晓玲, 段彦彦, 汤昱   

  1. 郑州大学附属儿童医院,河南省儿童医院, 河南 郑州 450000
  • 收稿日期:2020-09-02 修回日期:2020-11-23 出版日期:2021-02-28 发布日期:2021-02-28
  • 基金资助:
    河南省医学科技攻关计划联合共建项目(项目编号:LHGJ20190974)

The Efficacy and Pharmacoeconomic of Different Treatments Evaluation for Children with Cough Variant Asthma

  1. Children′s Hospital Affiliated to Zhengzhou University, Children′s Hospital of Henan Province,Henan Zhengzhou 450000, China
  • Received:2020-09-02 Revised:2020-11-23 Online:2021-02-28 Published:2021-02-28

摘要: 目的:探讨2种不同方案治疗儿童咳嗽变异性哮喘的疗效及药物经济学。方法:采用回顾性分析方法,纳入本院2019年1~12月进行治疗的4~6岁咳嗽变异性哮喘患儿420例。依据不同治疗方案分为A、B两组,其中A组269例,应用丙酸氟替卡松吸入气雾剂治疗;B组151例,应用沙美特罗替卡松粉吸入剂治疗。分析患儿的治疗效果、肺功能指标、不良反应、成本效果(C/E)、敏感性。结果:A、B两组总有效率分别为95.54%、93.37%,A组稍高于B组,两组间无统计学差异(P>0.05);经治疗两组间患儿肺功能指标改善情况和不良反应对比,均无统计学差异(P>0.05);A组和B组C/E分别为19.72和23.53,△C/△E为-144.23,A组C/E低于B组;当药品价格下降10%时,A组和B组C/E分别为19.00和22.47,△C/△E为-130.23,A组C/E低于B组。结论:儿童咳嗽变异性哮喘,应用丙酸氟替卡松吸入气雾剂治疗效果较好,药物经济学价值较高。

关键词: font-size:medium, ">儿童;咳嗽变异性哮喘;氟替卡松;沙美特罗氟替卡松;药物经济学

Abstract: Objective: To explore the efficacy and pharmacoeconomic of 2 different treatments for children with cough variant asthma. Methods: A retrospective study was used to include 420 children with cough variant asthma aged 4-6 years who were treated in our hospital from January to December 2019. According to different treatments, they were divided into groups A and B. Among them, 269 patients in group A were treated with fluticasone, 151 patients in group B were treated with salmeterol fluticasone. The treatment effect, lung function indexes, adverse reactions, cost-effectiveness (C/E) and sensitivity of the children were analyzed. Results: The curative effects of group A and group B were 95.54% and 93.37% respectively. The total effective rate of group A was higher than that of group B, but there was no statistical difference (P>0.05). There was no statistically significant difference in the improvement of pulmonary function indexes and adverse reactions between the two groups after treatment (P>0.05). The C/E of Group A and Group B were 19.72 and 23.53, △C/△E was -144.23, and the C/E of Group A was lower than that of Group B. When the drug price dropped by 10%, the C/E of Group A and Group B were 19.00 and 22.47, △C/△E was -130.23, and the C/E of Group A was lower than that of Group B. Conclusion: Children with cough variant asthma, treated with fluticasone propionate inhalation aerosol, has good effect and high pharmacoeconomic value.
 

Key words: font-size:medium, ">Children;Cough variant asthma;Fluticasone;Salmeterol fluticasone;Pharmacoeconomics

中图分类号: